EXECUTIVE TEAM
img

Mark Blumling

CEO, Founder, and Board Member mark.blumling@headlandsresearch.com

A passionate advocate of healthcare and life sciences innovation, Mark has devoted his career to improving population health and patient outcomes. Mark was previously CEO of Genos, a healthcare big data company (which he co-founded and which was acquired in 2017), CEO of Relevare Pharmaceuticals (a drug development pharmaceutical company based in San Francisco and Australia), and Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015). Mark began his career in the Office of Science & Technology at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH), where he helped lead the company’s successful turnaround.

Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.

img

Lauren Chazal

Chief Business Development Officer (CBDO) lauren.chazal@headlandsresearch.com

Lauren Chazal has a strong command of the clinical trials industry from a site operations, business development and financial management perspective. She began her career in clinical trial operations with a privately-held multi-site clinical research organization. Since 2012, she has held a pivotal role in business development and relationship management for clinical research sites globally. Lauren has in-depth knowledge of the complex interactions between clinical research centers, CROs and sponsors combined with a keen understanding of the importance of access to high quality trial sites and patient recruitment solutions.

Lauren graduated from Lehigh University with a dual degree in Finance and Marketing and from the University of Florida with a Master's in Business Administration (MBA). Lauren is a current member of Healthcare Businesswomen’s Association (HBA) and International Women’s Forum (IWF) Arizona Chapter as well as a four time marathon runner.

Meet Lauren Q&A

img

Cathy Collins

Senior Vice President Site Strategy/Development cathy.collins@headlandsresearch.com

Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).

Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.

Meet Cathy Q&A

img

James N. Goldenberg, MD - CPI, FAAN, FAPCR

Chief Medical Officer and Key Opinion Leader - Neurology james.goldenberg@headlandsresearch.com

Dr. James Goldenberg is a Board-Certified Neurologist who practiced in Palm Beach County, Florida for 25 years. He currently serves as Chief Medical Officer for Headlands Research and Sr. Vice President and Associate Medical Director of JEM Research Institute.

He previously served as Medical Director for Atlantic Coast Health Network, a regional super clinically integrated network (CIN), representing over 1,900 physicians and 200,000 lives in South Florida. In that role he is responsible for strategy, value-based care initiatives, population health and patient safety.

Dr. Goldenberg has served JFK Hospital in Atlantis Florida in multiple leadership roles including Chairman of the Board of Trustees Dr. Goldenberg has also served The Joint Commission as a disease-specific surveyor in stroke, the first physician to hold that position nationally. Dr. Goldenberg is an Affiliated Assistant Professor of Neurology at the Leonard M. Miller School of Medicine at the University of Miami.

Dr. Goldenberg is an advocate for patients and physicians at the local, regional, and national levels. He is a past president of the Palm Beach County Medical Society and currently serves on the Board of Directors. He has served the Florida Medical Association on the Board of Governors and the Council on Medical Economics and Practice Innovation. He is serving the American Academy of Neurology on the Board of Directors, Advocacy Committee, and chairs the Business Innovation Subcommittee.

His undergraduate training is in Psychology from the University of Florida. He received his Medical Degree from the University of South Florida. His neurology training and fellowship in neuromuscular disease were completed at the University of Miami.

Meet James Q&A

img

Autumn Huiatt

Chief Financial Officer autumn.huiatt@headlandsresearch.com

Autumn Huiatt brings years of accounting, finance, and operations experience to Headlands Research. Prior to joining Headlands, Autumn was CFO of Microsurgical Technology, Inc., a designer and manufacturer of ophthalmic surgical instrumentation for use in cataract and glaucoma surgeries.

Autumn also held a variety of roles at Sound Inpatient Physicians, Inc., a nationwide physician partner to hospitals, physician groups, and post-acute providers. Her roles at Sound Physicians included Vice President of Operations for Managed Care Services as well as Controller and Vice President of Accounting where she gained experience in a fast-growing clinical site business, acquisition integration, system implementation and optimization, process improvement and internal controls development.

Autumn holds an active CPA license (WA), earned her MBA at The Wharton School of the University of Pennsylvania and graduated with an accounting degree from the University of Jamestown in North Dakota. Autumn started her career in public accounting at Deloitte.

img

Ann Mao

General Counsel ann.mao@headlandsresearch.com

Ann Mao brings a wealth of experience to the Headlands Research team. Prior to joining Headlands Research, Ann served as the Chief Legal Officer of Cargomatic, Inc., a logistics services company, where she was responsible for the legal, compliance and regulatory functions and a member of the Executive team.

From 2008 to 2017, Ann worked for McKesson Corporation, a leading pharmaceutical distributor and healthcare company. Her last role at McKesson was as Senior Vice President, Corporate Strategy and Business Development, responsible for acquisitions, divestitures, equity investments and joint ventures across the McKesson portfolio of businesses. During her time in this role, Ann worked on transactions which deployed over $15 billion in capital.

Ann started her legal career in private practice at Shearman & Sterling.

img

Heather Abbis

Vice President of Finance heather.abbis@headlandsresearch.com

Heather Abbis brings over 25 years of operational and corporate finance experience to Headlands. Her experience spans start-ups to large public companies in the US and Europe with life science and medical device companies. Her focus has always been on process improvement and internal controls that enable financial operations to run more smoothly and enhance governance. She has a record of successfully managing change through growth and acquisitions, implementing systems, building teams and business partnerships. Her experience covers the full accounting cycle and planning for growth that will be a key factor as the Headlands network grows.

Heather received her MBA in international business from European University and holds a Bachelor of Science degree in Accounting from Rochester Institute of Technology.

img

Molly Brock

Vice President of Operations molly.brock@headlandsresearch.com

Molly Brock has more than 15 years of clinical research experience. Molly's industry experience includes a large academic medical center, health systems, and most recently, a prominent Clinical Research Organization (CRO). Molly has held numerous leadership positions in operations, development, and site partnerships. Her diverse background includes establishing large clinical trial centers and spearheading global divisions in the CRO sector. Molly's focus is to continue fostering the crucial relationship between clinical trial sites and sponsors. Molly received her B.A. in Chemistry and her Master's degree in Clinical Research Organization and Management from Drexel University.

img

Sarah Buck

Vice President of Human Resources sarah.buck@headlandsresearch.com

Sarah Buck brings 20 years of generalist and specialist HR tenure to Headlands. Her experience includes Recruitment, Labor/Employee Relations, M&As, Org Design, and Business Partner leadership roles where she worked with executives to implement results-driven people strategies. She possesses expertise in creating and implementing best in class HR programs, while navigating through accelerated growth and high-change environments. Sarah’s career spans multiple industries, most recently in healthcare where she led HR for a growing 33 site medical network which doubled its size in less than three years. Her passion for blending company objectives with the recognition of employees as individuals will propel Headlands as a best place to work.

Sarah received her Master’s degree in Industrial Relations from the University of Wisconsin-Madison and holds a Bachelor of Human Resource Management from the University of Northern Iowa.

Meet Sarah Q&A

img

Chris Cugliari

Director of Corporate Development chris.cugliari@headlandsresearch.com

Chris Cugliari joined Headlands Research as Director of Corporate Development and brings a demonstrated history of capturing full value of M&A transactions. He was previously the Manager of Corporate Development and Strategy for Sotera Health, where his leadership drove significant growth and expanded the company’s total addressable market in the lab testing and contract sterilization segments for medical devices and pharmaceuticals. As a previous M&A consultant for PwC, Chris served clients across a wide range of industries and sizes through complex deal issues. His deep transactional knowledge from targeted prospecting through robust due diligence and integration helps position Headlands Research for growth.

Chris graduated from Columbia Business School with an MBA and from the University of Notre Dame with a BBA in Information Technology Management.

Meet Chris Q&A

BUSINESS DEVELOPMENT
img

Lauren Chazal

Chief Business Development Officer (CBDO) lauren.chazal@headlandsresearch.com

Lauren Chazal has a strong command of the clinical trials industry from a site operations, business development and financial management perspective. She began her career in clinical trial operations with a privately-held multi-site clinical research organization. Since 2012, she has held a pivotal role in business development and relationship management for clinical research sites globally. Lauren has in-depth knowledge of the complex interactions between clinical research centers, CROs and sponsors combined with a keen understanding of the importance of access to high quality trial sites and patient recruitment solutions.

Lauren graduated from Lehigh University with a dual degree in Finance and Marketing and from the University of Florida with a Master's in Business Administration (MBA). Lauren is a current member of Healthcare Businesswomen’s Association (HBA) and International Women’s Forum (IWF) Arizona Chapter as well as a four time marathon runner.

Meet Lauren Q&A

img

Mauro Ormedilla

Director of Business Development mauro.ormedilla@headlandsresearch.com

Hailing from Buenos Aires, Argentina, Mauro brings over 8 years’ experience leading clinical research sites. He has been responsible for business development, operations, accounting, finance, marketing, advertising, recruitment, QA, start-up, and regulatory teams. Prior to joining Headlands, Mauro served as the Director of Operations for a multi-site clinical research group, which grew ten-fold during his tenure. His passion lies in making connections – trials to patients, Sponsors/CROs to sites, CROs to Sponsors, and new friends to old.

Mauro graduated from the University of California San Diego with a degree in Human Development and received his MBA from Loyola University in New Orleans. He loves to golf, play basketball, and watch the Mardi Gras floats parade down St. Charles Avenue.

Meet Mauro Q&A

img

McKenzie Lang

Associate Director of Business Development mckenzie.lang@headlandsresearch.com

McKenzie Lang possesses a deep understanding of clinical research through her years of experience representing sites within the US and internationally. McKenzie understands the importance of clinical trials and how site networks play an integral role in expediting the drug development process. McKenzie has worked for several site organizations, including Bioclinica and Wake Research, over the past decade and understands the importance of strong collaborative Industry relationships that benefit patients. McKenzie is located in Raleigh, NC.

McKenzie graduated from East Carolina University with a B.S. in Biology.

Meet McKenzie Q&A

img

Kayla Kramschuster

Global Feasibility Analyst kayla.kramschuster@headlandsresearch.com

Kayla Kramschuster joined the Headlands Research team as the Global Feasibility Analyst. Kayla has previous work experience in the healthcare realm and Clinical Trials research in particular. Most recently as a Clinical Trials Data Coordinator for the Precision Medicine Team at the University of Wisconsin's Carbone Cancer Center. Kayla will be working closely with the Business Development team to deliver robust feasibilities to Headlands sites within defined scope and timelines.

Kayla graduated from the University of Wisconsin with a B.S degree in Community and Environmental Sociology and Environmental Studies and currently lives in Madison, Wisconsin with her dog Brady.

Meet Kayla Q&A

OPERATIONS
img

Cathy Collins

Senior Vice President Site Strategy/Development cathy.collins@headlandsresearch.com

Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).

Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.

Meet Cathy Q&A

img

James N. Goldenberg, MD - CPI, FAAN, FAPCR

Chief Medical Officer and Key Opinion Leader - Neurology james.goldenberg@headlandsresearch.com

Dr. James Goldenberg is a Board-Certified Neurologist who practiced in Palm Beach County, Florida for 25 years. He currently serves as Chief Medical Officer for Headlands Research and Sr. Vice President and Associate Medical Director of JEM Research Institute.

He previously served as Medical Director for Atlantic Coast Health Network, a regional super clinically integrated network (CIN), representing over 1,900 physicians and 200,000 lives in South Florida. In that role he is responsible for strategy, value-based care initiatives, population health and patient safety.

Dr. Goldenberg has served JFK Hospital in Atlantis Florida in multiple leadership roles including Chairman of the Board of Trustees Dr. Goldenberg has also served The Joint Commission as a disease-specific surveyor in stroke, the first physician to hold that position nationally. Dr. Goldenberg is an Affiliated Assistant Professor of Neurology at the Leonard M. Miller School of Medicine at the University of Miami.

Dr. Goldenberg is an advocate for patients and physicians at the local, regional, and national levels. He is a past president of the Palm Beach County Medical Society and currently serves on the Board of Directors. He has served the Florida Medical Association on the Board of Governors and the Council on Medical Economics and Practice Innovation. He is serving the American Academy of Neurology on the Board of Directors, Advocacy Committee, and chairs the Business Innovation Subcommittee.

His undergraduate training is in Psychology from the University of Florida. He received his Medical Degree from the University of South Florida. His neurology training and fellowship in neuromuscular disease were completed at the University of Miami.

Meet James Q&A

img

Molly Brock

Vice President of Operations molly.brock@headlandsresearch.com

Molly Brock has more than 15 years of clinical research experience. Molly's industry experience includes a large academic medical center, health systems, and most recently, a prominent Clinical Research Organization (CRO). Molly has held numerous leadership positions in operations, development, and site partnerships. Her diverse background includes establishing large clinical trial centers and spearheading global divisions in the CRO sector. Molly's focus is to continue fostering the crucial relationship between clinical trial sites and sponsors. Molly received her B.A. in Chemistry and her Master's degree in Clinical Research Organization and Management from Drexel University.

img

Andrea Hunnicutt

Senior Director of Operations andrea.hunnicutt@headlandsresearch.com

Andrea Hunnicutt has an extensive and diverse background in medicine, hospital management, and clinical research. She began her career in veterinary medicine as a registered veterinary technician. Andrea managed multiple large general medicine and specialty practices prior to moving into the research field. Most recently Andrea worked for a large Clinical Research Organization in numerous roles from study startup to closeout in Phase I-IV trials. She has over 6 years of in-depth experience in site management, GCP compliance, regulatory affairs, and patient safety. Andrea is passionate about site and sponsor collaboration with an ultimate goal of improving patient outcomes through innovative technology and medical advancements.

Andrea graduated from Fort Hays State University with a B.S in Sociology and holds a Master’s degree in Clinical Research from The Ohio State University.

img

Derek Kern

Senior Director of Regional Operations derek.kern@headlandsresearch.com

Derek Kern joins Headlands Research with extensive experience across the clinical research space. Derek began his career as a Quality Analyst for a cGMP manufacturing operation. He went on to be a Project Manager for a large academic medical center and Associate Director for an NCI designated cancer center. Most recently, he was a Senior Manager of Clinical Operations for a prominent Clinical Research Organization (CRO) where he worked to optimize site start-up operations. Derek brings with him a passion for the advancement of healthcare and the improvement of patients’ quality of life.

Derek graduated from The University of Kansas with a B.A. in Human Biology. He is a Certified Clinical Research Professional.

BOARD MEMBERS
img

Mark Blumling

CEO, Founder, and Board Member mark.blumling@headlandsresearch.com

A passionate advocate of healthcare and life sciences innovation, Mark has devoted his career to improving population health and patient outcomes. Mark was previously CEO of Genos, a healthcare big data company (which he co-founded and which was acquired in 2017), CEO of Relevare Pharmaceuticals (a drug development pharmaceutical company based in San Francisco and Australia), and Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015). Mark began his career in the Office of Science & Technology at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH), where he helped lead the company’s successful turnaround.

Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.

img

Cathy Collins

Senior Vice President Site Strategy/Development cathy.collins@headlandsresearch.com

Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).

Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.

Meet Cathy Q&A

img

Anuv Ratan

Headlands Board Member

Anuv Ratan joined KKR in 2017 and is a member of the Health Care industry team. At KKR, he has been involved with investments in Gamma Biosciences, Impel Neuropharma, Headlands Research, BrightSpring Pharmerica, Global Medical Response, Ajax Health, and Aimmune Therapeutics. He is currently a member of the board of directors of Gamma Biosciences, Blue Sprig Pediatrics, and Headlands Research. Prior to joining KKR, Mr. Ratan was with FFL Partners, where he was involved in a number of health care transactions. Mr. Ratan began his career at The Blackstone Group. He holds an A.B., with honors, in Neurobiology from Harvard University.

img

Ali Satvat

Headlands Board Member

Ali J. Satvat joined KKR in 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. He leads KKR’s Health Care Strategic Growth investing efforts, sits on the Health Care Strategic Growth Investment Committee and is Chairman of the Health Care Strategic Growth Portfolio Management Committee. He currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Clarify Health Solutions, Cohera Medical, Coherus BioSciences, Eidos Therapeutics, Headlands Research, Impel NeuroPharma, Slayback Pharma, and Trilogy MedWaste and has been involved in KKR’s investments in Ajax Health, PRA Health Sciences, and Spirox. Previously, he held various positions with Apax Partners, Johnson & Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. He is a member of the board of directors of the Healthcare Private Equity Association.

ADVISORS
img

David Evans

CEO, Texas Neurology

David Evans is CEO of Texas Neurology, among the largest and most comprehensive neurology practices in the country. He is extremely active in the American Academy of Neurology where he currently serves as Chair of the AAN’s Practice Management & Technology Subcommittee and is Past Chair of the Business section. He is also a member of the AAN’s Medical Economics & Management Committee and BrainPAC Executive Committee. Mr. Evans has extensive background in practice management consulting with emphasis in the implementation of ancillary services within physician practices.

img

David Kopp

Former CEO, Healthline Media & Strategic Advisor

David Kopp is an experienced chief executive in consumer digital health with expertise spanning strategy, product development, marketing, and technology. Most recently, David led a passionate and highly successful team at Healthline Media, spearheading global growth to reach more than 350 million monthly visitors and more than any other health publisher.

David brings deep expertise in consumer-driven digital health businesses, particularly in growth marketing, scaling teams and culture, and digital strategy.

img

Jim Kremidas

Former Executive Director at Association of Clinical Research Professionals (ACRP)

Jim Kremidas has over 35 years of experience in the health care industry. Most recently he has served as the Executive Director for the Association of Clinical Research Professionals (ACRP). Prior to that he worked with Investigator Sites, Suppliers and Pharma Companies to advise them on clinical research operations. He has over 7 years of experience in management at CROs and spent 24 years at Eli Lilly and Company where he started the first Patient Recruitment Department in the industry.

As an internationally renowned thought leader, Jim advises on topics related to the innovative design, implementation and tracking of successful clinical trial operations. His leadership roles have included strategic planning, organizational change management, training/staff development, negotiations/contracting, business development and implementation of innovative programs across the clinical development enterprise. Jim has extensive experience in building cross functional relationships and strong enterprise collaboration to drive organizational change, supplier management, negotiations, marketing management and clinical trial operations. Jim sits on several national committees and has been a volunteer leader for Center for Information and Study of Clinical Research Participation (CISCRP), a non-profit organization. He has also participated in Clinical Trial Transformation Initiative (CTTI) subcommittees.

img

Craig Lipset

Former Head of Innovation, Pfizer

Craig Lipset is a recognized leader at the forefront of innovation in clinical research and medicine development. He is an advisor to technology and biopharmaceutical companies, leading universities, and the venture community, bringing vision and driving action at the intersection of research, digital solutions, and patient engagement. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures (Perceptive Informatics and Adnexus Therapeutics).

During that time, Craig designed and launched multiple industry firsts -- from the first fully remote/virtual clinical trial for a new medicine to the first returning of results and data to research participants. He currently serves on the Board of Directors for the Foundation for Sarcoidosis Research, the MedStar Health Research Institute, and the People-Centered Research Foundation (the central office for PCORnet), as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science. Craig has received the red jacket 'hall of fame' recognition among the PharmaVOICE most inspiring people in the life sciences. He has been recognized among Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, the Medicine Maker Power List and the AlleyWatch Who's Who in eHealth. He studied Music at Brandeis University and earned a Master of Public Health from Columbia.

img

Dr. Bola Oyegunwa PhD

Vice President and Head of Virtual Trials, Covance

Dr. Bola Oyegunwa is the Vice President and Head of Virtual trials at Covance. Bola is an industry thought leader in developing and implementing virtual trial solutions and disruptive technology offerings. Bola has led the implementation of innovative technology-enabled hybrid and virtual trials solutions for leading Biotech and pharmaceutical companies. Bola is a champion for reducing patient burden in clinical trials and regularly engages with regulatory authorities globally to remove regulatory barriers to the adoption of virtual clinical trials.

Bola is an ex-strategy consultant and has held leadership roles in Corporate Strategy, Product Development and Innovation at leading CROs. He holds a PhD in Microbiology and Immunology and a MBA from North Carolina State University.

img

Jane Restorick

Consultant and Managing Director, Arion Services

Jane Restorick is a recognized expert in site management, patient recruitment and clinical research operations. Prior to moving into consultancy, Jane was COO and Chief Patient Officer at Synexus Clinical Research, driving its growth from a UK based SMO to become a successful international operation across 11 countries. Previously she formed and led Operations and Quality Management teams at a virtual biopharma (Vanguard Medica) and at Fujisawa Early Clinical Evaluation Unit.

KEY OPINION LEADERS
img

Larry Bush - MD

Key Opinion Leader - Infectious Disease and Vaccine

Dr. Larry Bush has practiced the specialized field of Infectious Diseases in Palm Beach County, Florida, since 1989. He is involved in organized medicine and has served many roles, including President of the Palm Beach County Medical Society (PBCMS), which is a network of 1,500 physicians in the Palm Beach County area.

Dr. Bush has developed a portfolio of influential positions locally, regionally, and nationally. He is committed to the scientific process and has participated in a multitude of clinical trials throughout his career. He maintains close academic affiliations and is dedicated to educating the next generation of physicians, relishing the opportunity to teach students and residents.

Dr. Bush has held leadership positions in several hospitals including multiple positions as committee chair in Infectious Disease stewardship, credentialing, quality, pharmacy, research, and medical executive leadership. He has served on the Board of two local hospitals, culminating in a term as Board chair. He holds the academic positions of Affiliated Professor of Medicine at the Charles E. Schmidt College of Medicine at Florida Atlantic University as well as Affiliated Associate Professor of Medicine at University of Miami Miller School of Medicine. Through his academic affiliations, Dr. Bush has trained countless internal medicine residents, many of whom have gone on to fellowships and careers in Infectious Diseases.

Dr. Bush has authored over 90 peer-reviewed medical journal articles. He is a current associate editor of two national Infectious Diseases journals, and continues to author book chapters in medical reference literature and has conducted over 100 infectious disease research trials, including vaccine trials.

Dr. Larry Bush received his bachelor’s degree in Biology from the University of Pennsylvania and his Medical Degree from the Medical College of Pennsylvania. Subsequently, he did his residency in Internal Medicine at the Pennsylvania Hospital of the University of Pennsylvania Health System, where he went on to serve as Chief Medical Resident for one year. He completed specialty training as a fellow in Infectious Diseases at the Medical College of Pennsylvania before relocating to South Florida.

img

Sharon Cohen - MD, FRCPC

Key Opinion Leader - Neurology

Dr. Sharon Cohen is a behavioural neurologist known for her excellence in patient care, teaching, and clinical research. She completed her neurology residency and behavioural neurology fellowship at the University of Toronto. She is the medical director and site principal investigator of Toronto Memory Program, a community-based medical facility which she established in 1996 for the purpose of enhancing diagnosis, care, and therapeutic options for individuals with or at risk for Alzheimer’s disease and related disorders. Under her guidance, Toronto Memory Program’s multidisciplinary team has grown to a staff of 30 individuals. Its memory clinic and research site are among the most active in Canada.

Dr. Cohen has over 28 years of experience in clinical research and has been a site PI for over 100 pharmacological trials. She has participated in acute stroke trials as well as trials in FTD, PDD, DLB, HD, vascular dementia, and Alzheimer’s disease, the latter being her primary focus. Her site has been credited as a “go to” centre for Alzheimer’s trials and has been awarded for superior performance and quality in clinical research.

Dr. Cohen represents Canada on international advisory boards and steering committees and is a consultant to a wide range of stakeholders in dementia including government organizations and patient advocacy groups. She is a frequent lecturer and contributes to media events including those on medical ethics. She is known for her advocacy of individuals with neurodegenerative diseases.

Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real world setting.

img

James N. Goldenberg - MD - CPI, FAAN, FAPCR

Chief Medical Officer and Key Opinion Leader - Neurology

Dr. James Goldenberg is a Board-Certified Neurologist who practiced in Palm Beach County, Florida for 25 years. He currently serves as Chief Medical Officer for Headlands Research and Sr. Vice President and Associate Medical Director of JEM Research Institute.

He previously served as Medical Director for Atlantic Coast Health Network, a regional super clinically integrated network (CIN), representing over 1,900 physicians and 200,000 lives in South Florida. In that role he is responsible for strategy, value-based care initiatives, population health and patient safety.

Dr. Goldenberg has served JFK Hospital in Atlantis Florida in multiple leadership roles including Chairman of the Board of Trustees Dr. Goldenberg has also served The Joint Commission as a disease-specific surveyor in stroke, the first physician to hold that position nationally. Dr. Goldenberg is an Affiliated Assistant Professor of Neurology at the Leonard M. Miller School of Medicine at the University of Miami.

Dr. Goldenberg is an advocate for patients and physicians at the local, regional, and national levels. He is a past president of the Palm Beach County Medical Society and currently serves on the Board of Directors. He has served the Florida Medical Association on the Board of Governors and the Council on Medical Economics and Practice Innovation. He is serving the American Academy of Neurology on the Board of Directors, Advocacy Committee, and chairs the Business Innovation Subcommittee.

His undergraduate training is in Psychology from the University of Florida. He received his Medical Degree from the University of South Florida. His neurology training and fellowship in neuromuscular disease were completed at the University of Miami.

Meet James Q&A

img

Vishaal Mehra - MD

Dr. Vishaal Mehra attended Texas A&M Health Science Center for his Medical Degree, and then completed his residency in Psychiatry at the University of California, San Diego. He began his career as an Investigator in clinical research in 2007.

As a Principal Investigator, Dr. Mehra worked in a variety of psychiatry and neurology therapeutic areas. He also worked closely with Sponsors and CROs to promote study-wide trial success, acting as a liaison for other Principal Investigators and the sponsor for several trials. Dr. Vishaal Mehra founded Artemis Institute for Clinical Research in 2008.

img

Mark A. Goldstein - MD CPI, FAPCR

Key Opinion Leader - Neurology

Dr. Goldstein was born and raised in New York City. He graduated Colgate University, receiving a B.A. degree with a major in Biophysics. He obtained his MD degree from Emory University School of Medicine in Atlanta. Upon graduation, he completed residencies in both Internal Medicine (College of Medicine and Dentistry of New Jersey/Robert Wood Johnson) and Neurology (Stanford University). He is board certified in both Internal Medicine and Neurology. After relocating to South Florida, he joined a busy clinical neurology practice which he helped grow to 6 Neurologists.

Dr. Goldstein began participating in clinical trials in the late 1990’s. To date, he has participated in over 80 clinical trials, being the Principal Investigator 70 times. Most of these trials have been conducted through JEM Research Institute, of which he is a founding member and the CEO. Under his guidance, JEM has grown into a substantial clinical research site currently employing 26 people, and conducting over 20 active trials at any one time, many of which deal with progressive cognitive decline.

As a clinical neurologist, Dr. Goldstein serves as an Affiliated Assistant Clinical Professor of Neurology at the University of Miami. As a researcher, he is a Certified Principal Investigator as well as a Fellow of the Academy of Physicians in Clinical Research.

Dr. Goldstein has served on the board of directors of the Medical Specialists of The Palm Beaches, the largest multispecialty medical group in Palm Beach County. He has also been a member of the executive committee as well as chairman of the credentials committee at JFK Hospital in Atlantis. He has been both the Chief of the Division of Neurology and the Director of the Comprehensive Stroke Center at JFK.